Review Objective
The objective of this review is to synthesize the best available evidence on the effectiveness of individualised survivor care plans as compared to usual care on quality of life for adult female breast cancer survivors.
Review Question
In the adult female breast cancer survivor what is the effect of an individualised survivorship care plan as compared to usual care on quality of life?
Background
Breast cancer is cancer (malignant cells) that develops in the breast tissue 1,2 . Characteristic signs and symptoms may be no symptoms, alteration in the breast tissue such as skin changes, breast pain, lumps in the breast tissue, discharge from the nipple or swelling in the axilla 1, 2 . It is most commonly seen in the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk) 1.2 . This type of cancer is most common in women worldwide, comprising 16% of all female cancers 3 . The National Cancer Institute's (NCI) call to strengthen efforts for cancer care nationwide was demonstrated by a bill known as the National Cancer Act of 1971. Since that time, the number of cancer survivors in the United States (US) has increased from three million to over twelve million in 2012 1 . Breast cancer survivors make up the largest group of cancer survivors (22%) and according to the US National Institute of Health (NIH), there are more than 2.5 million breast cancer survivors in the United States 1 . Worldwide, breast cancer survivor rates vary greatly. These can range from 80% in North America, Sweden, and Japan, to less than 40% in developing and low income countries Breast cancer survivors are defined as women who have completed treatment for breast cancer and are considered cured, but who continue to experience the emotional and physical impact of the disease 6 . The survivor population is growing, due to novel therapies and advances in medicine. Knowledge and skills need to be enhanced to understand the bio-psychosocial and cultural aspects of breast cancer survivors and to improve strategies for delivering quality health care and outcomes.
Quality of life for survivors is a multidimensional construct 7 . It has different meanings for each survivor and is the assessment of the survivors overall well-being 8 . . The transition back to the primary care provider does not guarantee continuity of care.
Primary care providers are not experts in oncology care or the sequela of post procedural interventions, chemotherapy and radiation modalities. Breast cancer survivors have exclusive needs and concerns and are left with many side effects, fears, and unanswered questions [7] [8] [9] . At least 50% of cancer survivors suffer from late treatment-related side effects, often including physical, psychosocial, cognitive and sexual abnormalities, decreased energy, sleep disturbances, mood alterations, as well as concerns regarding recurrence and/or the development of new malignancies [10] [11] [12] [13] [14] [15] [16] [17] . In addition, women endure changes in body image, fertility problems, menopausal symptoms, co-morbidities, emotional disturbances, and employment and health insurance issues [16] [17] . Female breast cancer survivors have diverse needs based on age and may not have the ability to care for themselves in a holistic manner after discharge from the oncology team. These survivors have varying levels of knowledge, health literacy, education, financial resources, social support, and cultural health care belief patterns [18] [19] . When cultural beliefs are incorporated into the treatment plan, patients are more satisfied and continue treatment 20 .
According to the American Cancer Society, breast cancer survivorship is improving with the advancement of treatment modalities 21 . Coordination of care is a priority as breast cancer survivors return to their primary care providers for ongoing care 22, 23 . Patient satisfaction, optimal health outcomes, and quality of life are very much a quality standard for primary care providers in the current healthcare environment.
Primary care providers have to demonstrate efficient and productive practices while delivering comprehensive quality healthcare 24 Primary care providers in collaboration with the oncologist and other specialists can provide optimal preventative and recommended care for survivors and disease processes
when communication remains open between the health care team 22, 23 . An individualised survivorship care plan is a beneficial method that can be put into place to guide healthcare providers and patients working as a team after active cancer treatment 23, 25 . The care plan is a document summarizing the patient's cancer treatment, experiences and side effects 25 . Primary care providers will be challenged as millions of survivors transition from treatment to living life post treatment 23 . Survivors will be searching for specific guidelines to optimize their health and evaluate biopsychosocial issues, and require resources to support their overall health 23, 26 . Primary care providers will need to be knowledgeable about the effects of cancer survivor therapies and beyond 24 . Acquiring knowledge and skills to optimise care quality for breast cancer survivor issues and facilitating access to interventions for follow-up and surveillance can empower primary care providers and survivors with resources that will support post treatment rehabilitation.
In the US, the Institute of Medicine (IOM) 27 and National Research Council (NRC) 28 . An individualised survivorship care plan may be effective for both the survivor and the primary care provider when efforts are made to control cancer recurrence and minimise cancer related toxicities in combination with meeting the patient's oncological and primary care
needs for improved quality of life.
An initial search of MEDLINE, CINAHL, PsycINFO, DARE, PROSPERO, The Joanna Briggs Institute
Library of Systematic Reviews, and the Cochrane Database of Systematic Reviews was conducted for systematic reviews on this topic and no reviews were identified on the subject of whether individualised survivorship care plans impact on the quality of care as it relates to physical, psychosocial and sexual health for adult female breast cancer survivors.
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Inclusion criteria

Types of participants
This review will consider studies that include adult female breast cancer survivors, 18 years of age or older. A breast cancer survivor will be defined as one who has completed treatment for breast cancer and are considered cured, but who continue to experience the emotional and physical impact of the disease 7 .
The concept of survivorship and quality of life will cover the physical, psychosocial, and sexual issues of cancer.
Types of intervention/phenomena of interest
This review will consider individualised survivorship care plans as the additional intervention provided to adult female with breast cancer survivors receiving the standard or routine care.
The comparator: usual care. Usual care is standard or routine care for adult female breast cancer survivors.
Outcome measures:
This review will consider studies that include the following outcome measures: survivor's quality of life as it relates to physical, psychosocial, and sexual health. These outcome measures are critical components of survivorship care plans. Studies will be reviewed for evidence of standardised valid and reliable tools measuring quality of life in breast cancer survivors, such as the Long Term Quality of Life Breast Cancer (LTQOL-BC) scale 36 and the Cancer Rehabilitation Evaluation System-Short Form (CARES-SF) 37 . The LTQOL-BC measures seven domains which include physical, sexual and cognitive function, body image, coping, social support, and anxiety. The CARES-SF instrument assesses the rehabilitative and quality of life needs of cancer patients. The tool is a questionnaire with five sub-scales measuring quality of life domains that include physical, psychosocial, medical interaction, marital, and sexual. Other tools identified in the studies will be appraised for their reliability and validity.
Types of studies
This review will consider both experimental and epidemiological study designs including randomised controlled trials, non-randomised controlled trials, quasi-experimental, before and after studies, prospective and retrospective cohort studies, case control studies and analytical cross sectional studies as appropriate for inclusion.
Search Strategy
The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilized in this review. An initial limited search of MEDLINE and CINAHL will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly, the reference list of all identified reports and articles will be searched for additional studies. Studies published in English will be considered for inclusion in this review. Studies published from 1980 when this intervention was first introduced to present will be considered for inclusion in this review. 
Assessment of methodological quality
This review aims to synthesise the best available evidence. The purpose is to include the highest quality of evidence possible. The methodological quality of eligible studies will be assessed independently by two reviewers using the Joanna Briggs Institute (JBI) critical appraisal checklists for experimental studies, cohort/case control studies and descriptive/case series studies (Appendix I).
Papers selected for retrieval will be assessed by two independent reviewers for methodological quality prior to inclusion in the review using standardised critical appraisal instruments to assess the methodological quality of studies that aim to identify sources of bias with the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I). The randomised controlled and pseudo-randomised controlled trials chosen will meet a minimum of six out of 10 questions from the standardised critical appraisal instrument from JBI-MAStARI, with questions 1, 6, 7, 8, 9 and 10 being the most significant, to be considered of adequate quality for inclusion in the review. Chosen cohort/case control studies and descriptive/case studies will meet a minimum of five out of nine questions from the standardised critical appraisal instrument from JBI-MAStARI. Questions 1, 5, 7, 8, and 9 must be significant for cohort/case control studies and questions 1, 4, 7, 8, and 9 must be significant for descriptive/case series studies to be considered adequate quality for inclusion in the review. Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data Collection
Data will be extracted from papers included in the review using the standardised data extraction tool from JBI-MAStARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
Data Synthesis
Quantitative data will, where possible, be pooled in statistical meta-analysis, using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated for analysis as appropriate. Heterogeneity will be assessed statistically using the standard Chi-square and also explored using subgroup analyses based on the different study designs included in this review.
Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.
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